| |
|
|
|
|
|
 |
| |
|
±¤µ¿ ¼¼Æ÷´Ï½Ãµå³ªÆ®·ýÁÖ 1g
|
Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ(52)
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A22650571]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1º´(2007.03.01)(ÇöÀç¾à°¡)
\8,718 ¿ø/1º´(2003.03.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¡Û À¯È¿±ÕÁ¾
Æó·Å¿¬¼â±¸±Õ, Æó·Å°£±Õ, ´ëÀå±Õ, ÀÎÇ÷翣ÀÚ±Õ(¾ÏÇǽǸ° °¨¼ö¼º, ³»¼º), ÇÁ·Îºñµ§½Ã¾Æ ·¹Æ®°Ô¸®, ¸ð¸£°¡³Ú¶ó ¸ð¸£°¡´Ï, ÇÁ·ÎÅ׿콺 ºÒ°¡¸®½º, Ȳ»öÆ÷µµ±¸±Õ, Ç¥ÇÇÆ÷µµ±¸±Õ, ½ºÆ®·¾ÅäÄÛÄí½º ÇÇ¿À°Ô³×½º(±×·ìA-º£Å¸¿ëÇ÷¼º), ½ºÆ®·¾ÅäÄÛÄí½º ¾Æ°¥¶ôƼ¿¡(±×·ìB)
¡Û ÀûÀÀÁõ
- Çϱ⵵ °¨¿°Áõ
- ¿ä·Î°¨¿°Áõ
- ÇǺΠ¹× ÇǺÎÁ¶Á÷ °¨¿°Áõ
- °ñ ¹× °üÀý°¨¿°
- ¼ö¼ú ÈÄ °¨¿° ¹æÁö
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1. ¿ë·®
¡Û ¼ºÀÎ : ¼¼Æ÷´Ï½Ãµå·Î¼ Åë»ó 24½Ã°£¸¶´Ù 1 g(¿ª°¡)À» ±í°Ô ±ÙÀ°ÁÖ»çÇÑ´Ù. ´Ü¼ø¼º ¿ä·Î°¨¿°Áõ¿¡´Â 24½Ã°£¸¶´Ù 0.5 g(¿ª°¡)À» ÁÖ»çÇϰí ÁßÁõ°¨¿°Áõ¿¡´Â 24½Ã°£¸¶´Ù 1 g(¿ª°¡)À» ÁÖ»çÇÑ´Ù. ¼ö¼ú ÈÄ °¨¿° ¹æÁö¿¡´Â ¼ö¼ú 1½Ã°£ Àü¿¡´Â 1 g(¿ª°¡)À» ÁÖ»çÇϸç, »ý¸íÀ» À§ÇùÇÏ´Â °¨¿° ¹× ÁßÁõÀÇ °¨¿°Áõ¿¡´Â 24½Ã°£¸¶´Ù 2 g(¿ª°¡)±îÁö Áõ·®ÇÏ¿© ÁÖ»çÇÒ ¼ö ÀÖ´Ù. 1ÀÏ 1 gÀÌ»ó Ãʰú Åõ¿©ÇÏ´Â °æ¿ì´Â µå¹°Áö¸¸ ¿¹¿ÜÀûÀÎ °æ¿ì 1ÀÏ 1ȸ 2 g Åõ¿©ÇÏ¸é ³»¼ºÀÌ »ý±â±â ½±´Ù.
¡Û ½ÅÀå¾Ö ȯÀÚ : ÃÊȸ·® üÁß kg´ç 7.5 mg(¿ª°¡)À» ±ÙÀ°ÁÖ»çÇϰí À¯Áö¿ë·®Àº ¾Æ·¡ Ç¥¿Í °°ÀÌ Åõ¿©Çϸç, °è¼ÓµÇ´Â ¿ë·®Àº °¨¿°»óÅÂ, ¿øÀαÕÀÇ °¨¼ö¼º¿¡ µû¶ó °áÁ¤ÇÑ´Ù. ´Ù¸¸, Åõ¼® ÈÄ¿¡´Â Ãß°¡¿ë·®À» Åõ¿©ÇÒ Çʿ䰡 ¾ø´Ù.
|
Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²
(mL/min/1.73 m2)
|
°æ¹ÌÇÑ °¨¿° ¢¦ Áߵ°¨¿°
(mg/kg)
|
ÁßÁõ°¨¿°(mg/kg)
|
|
79 ¢¦ 60
59 ¢¦ 40
39 ¢¦ 20
19 ¢¦ 10
9 ¢¦ 5
< 5
|
10 (24½Ã°£ °£°Ý)
8 (24½Ã°£ °£°Ý)
4 (24½Ã°£ °£°Ý)
4 (48½Ã°£ °£°Ý)
4 (3 ¢¦ 5ÀÏ °£°Ý)
3 (3 ¢¦ 5ÀÏ °£°Ý)
|
25 (24½Ã°£ °£°Ý)
20 (24½Ã°£ °£°Ý)
15 (24½Ã°£ °£°Ý)
15 (48½Ã°£ °£°Ý)
15 (3 ¢¦ 5ÀÏ °£°Ý)
4 (3 ¢¦ 5ÀÏ °£°Ý)
|
2. ¿ë¹ý
±ÙÀ°ÁÖ»ç ½Ã¿¡´Â ³ÐÀº ±ÙÀ°ºÎÀ§¿¡ ÁÖ»çÇϸç 2 g(¿ª°¡)À¸·Î Áõ·®ÇÏ¿© ÁÖ»çÇÒ ¶§´Â 1 g(¿ª°¡)¾¿ ´Ù¸¥ ºÎÀ§¿¡ ÁÖ»çÇÑ´Ù.
|
| ±Ý±â |
1) ¼¼ÆÈ·Î½ºÆ÷¸°°è ¾à¹°¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
2) ¸®µµÄ«ÀÎ ¶Ç´Â ¾Æ´Ò¸®µå ±¹¼Ò¸¶ÃëÁ¦¿¡ ´ëÇØ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ(¸®µµÄ«ÀΠ÷°¡Á¦ Æ÷ÇÔ Ç°¸ñ¿¡ ÇÑÇÔ)
|
| ½ÅÁßÅõ¿© |
Æä´Ï½Ç¸°°è ¶Ç´Â ´Ù¸¥ ¾à¹°¿¡ °ú¹Î¹ÝÀÀ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ(ƯÈ÷ ¾à¹°¿¡ ´ëÇÑ º´·ÂÀÌ Àִ ȯÀÚ¿¡°Ô´Â Ç×»ý¹°ÁúÀ» ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. ÁßÁõÀÇ ±Þ¼º ¹ÝÀÀÀÌ ÀϾ °æ¿ì¿¡´Â ¿¡Çdz×ÇÁ¸° Åõ¿© ¹× ´Ù¸¥ ±ä±Þ¼ö´ÜÀ» ÃëÇÑ´Ù) |
| ÀÌ»ó¹ÝÀÀ |
1) °ú¹Î¹ÝÀÀ : µå¹°°Ô ¹ß¿, ¹ßÀû, °¡·Á¿ò, È«¹Ý, ±ÙÀ°Åë, ¾Æ´ÏÇʶô½Ã½º¸ð¾ç ¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) Ç÷¾×°è : µå¹°°Ô ¹éÇ÷±¸, È£Áß±¸, Ç÷¼ÒÆÇ °¨¼Ò°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, Ä¡·á Áß Äñ½º½ÃÇè¿¡ ¾ç¼ºÀ» ³ªÅ¸³¯ ¼ö°¡ ÀÖ´Ù.
3) ½ÅÀå : ¶§¶§·Î ÀϽÃÀûÀÎ BUN »ó½Â°ú Å©·¹¾ÆÆ¼´Ñ ³óµµÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. µå¹°°Ô ´Ù¸¥ ¼¼ÆÈ·Î½ºÆ÷¸°°è¿Í °°ÀÌ °£Áú¼º ½ÅÀå¿° ȯÀÚ¿¡°Ô ±Þ¼º ½ÅºÎÀüÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) °£Àå : ¶§¶§·Î ÀϽÃÀûÀÎ ALP, AST, ALT, ¥ã-GTP, LDH µîÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ¼Òȱâ°è : ¼³»ç, À§¸·¼º´ëÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ±¹¼Ò¹ÝÀÀ : ¶§¶§·Î ÁÖ»çºÎÀ§¿¡ ÅëÁõÀÌ ÀϾ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
¼¼ÆÈ·Î½ºÆ÷¸°°è ¶Ç´Â ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å°è Ç×»ý¹°Áú°ú º´¿ëÅõ¿©ÇÏ¸é ½Åµ¶¼ºÀÌ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: CEFONICID SODIUMMONOCID (CEFONICID SODIUM)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| BIT ¾àÈ¿ºÐ·ù |
2¼¼´ë ¼¼ÆÈ·Î½ºÆ÷¸°°è (Cephalosporins; Second Generation)
|
| º¹ÁöºÎºÐ·ùÄÚµå |
618 (ÁÖ·Î ±×¶÷¾ç¼º, À½¼º±Õ¿¡ ÀÛ¿ëÇÏ´Â °Í )
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cefonicid¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Cefonicid, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
|
| Pharmacology |
Cefonicid¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cefonicid is a second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
|
| Protein Binding |
Cefonicid¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 98% bound to plasma proteins.
|
| Half-life |
Cefonicid¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 4.5 hours
|
| Pharmacokinetics |
Cefonicid SodiumÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´Ü¹é°áÇÕ : 98%
- ´ë»ç : ´ë»çµÇÁö ¾Ê´Â´Ù.
- ¼Ò½Ç : ½Å¹è¼³
|
| Biotransformation |
Cefonicid¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not metabolized.
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cefonicid¿¡ ´ëÇÑ Description Á¤º¸ A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. [PubChem]
|
| Dosage Form |
Cefonicid¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Solution IntramuscularSolution Intravenous
|
| Drug Category |
Cefonicid¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsAntibacterial AgentsCephalosporins
|
| Smiles String Canonical |
Cefonicid¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ OC(C(=O)NC1C2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
|
| Smiles String Isomeric |
Cefonicid¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
|
| InChI Identifier |
Cefonicid¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13?,16-/m1/s1/f/h19,28,30H
|
| Chemical IUPAC Name |
Cefonicid¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-08-26
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. CEFONICID[GGT Increase][Composite Activity](Score) I(Marginal) 0(Active) 0[Alkaline Phosphatase Increase](Activity Score) I(Number of Rpts) <4(Index value) 12.7[SGOT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGPT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[LDH Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[GGT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|